Featured Research

from universities, journals, and other organizations

Screening for cervical cancer low for immigrant women, Canadian study suggests

Date:
February 2, 2011
Source:
St. Michael's Hospital
Summary:
Immigrant women in Ontario are not screened for cervical cancer as often as native-born Canadians, with the lowest rates being among older, poorer South Asians, new research shows.

Immigrant women in Ontario are not screened for cervical cancer as often as native-born Canadians, with the lowest rates being among older, poorer South Asians, new research shows.

Only one in five -- 21.9 per cent -- of South Asian immigrants over the age of 50 living in low-income neighbourhoods had had a recent Pap test, according to a study led by doctors at St. Michael's Hospital.

In contrast, 79 per cent of Canadian-born women living in the highest-income neighbourhoods and who had a primary care doctor were up-to-date with their cervical cancer screening. In Canada, federal and provincial guidelines call for a Pap test at least once every three years.

The study compared cervical cancer screening rates for immigrant and Canadian-born women living in urban areas of Ontario between 2006 and 2008. Overall, of the 2.9 million women ages 18 to 69 whose medical billing records were compared, 61.3 per cent were up-to-date.

The study, led by family physician Dr. Aisha Lofters, appeared in a recent edition of the journal Preventative Medicine.

"We need to reach out to the South Asian immigrant community and let them know the importance of the test," said Dr. Lofters, who is with the hospital's Center for Research on Inner City Health.

Dr. Lofters said the low screening rates for poorer, older South Asians may have a lot to do with culture and their experience in their homelands. Cervical cancer screening rates in many South Asian countries are quite low -- only 1 per cent in Bangladesh, even for those in the highest income strata.

"These women may not be coming from a culture where this is normal or practiced protocol," she said. "Some women were not even aware that they needed the test."

The length of time spent in Canada had little effect on a woman's screening rates. Even those who had been living in Canada for 10 or more years had rates similar to those who had recently immigrated, suggesting low patterns continue after immigration. Many of the women may be reluctant to see male doctors, Dr. Lofters said.

Cervical cancer is the second most common cancer among women worldwide. Rates are almost twice as high in the less developed world than the more developed world, where more people have Pap tests. The World Health Organization estimates that 95 per cent of women in less developed countries have never been screened and that screening every 5 to 10 years could significantly reduce deaths worldwide from cervical cancer.


Story Source:

The above story is based on materials provided by St. Michael's Hospital. Note: Materials may be edited for content and length.


Cite This Page:

St. Michael's Hospital. "Screening for cervical cancer low for immigrant women, Canadian study suggests." ScienceDaily. ScienceDaily, 2 February 2011. <www.sciencedaily.com/releases/2011/02/110202102750.htm>.
St. Michael's Hospital. (2011, February 2). Screening for cervical cancer low for immigrant women, Canadian study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/02/110202102750.htm
St. Michael's Hospital. "Screening for cervical cancer low for immigrant women, Canadian study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/02/110202102750.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins